Federal contract award
HHSO100201300010C
IGF::OT::IGF FOR OTHER FUNCTIONS THIS CONTRACT IS FOR THE CLINICAL DEVELOPMENT OF BAL30072, A NOVEL MONOSULFACTAM FOR THE TREATMENT OF INFECTIONS CAUSED BY MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL PATHOGENS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $13.1M |
| Current contract value | $13.1M |
| Potential contract value / ceiling | $85.2M |
| Start date | Jun 19, 2013 |
| Current end date | Sep 19, 2018 |
| Potential end date | Jun 1, 2019 |
| Latest award activity | Oct 23, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Oct 23, 2024 | P00010 | $0 | TO CLOSE THIS CONTRACT IN LINE WITH FAR 4.804, TO UPDATE THE CONTRACTING OFFICER TO DEVIN FITZMAURICE. |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.